Business Context and Reporting Period
Company: Septerna, Inc. (SEPN)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2024
Business Overview: Septerna is a clinical-stage biotechnology company developing oral small molecule therapies targeting G protein-coupled receptors (GPCRs) using its proprietary Native Complex Platform. The company focuses on endocrinology, immunology, inflammation, and metabolic diseases. Its lead product candidate, SEP-786, is an oral agonist for the Parathyroid Hormone 1 Receptor (PTH1R) for the treatment of hypoparathyroidism.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sept 30, 2024 | Nine Months Ended Sept 30, 2024 | Balance Sheet (Sept 30, 2024) |
|---|---|---|---|
| Revenue | $176 | $863 | N/A |
| Net Loss | $(20,523) | $(51,130) | N/A |
| Loss Per Share (Basic & Diluted) | $(8.40) | $(21.87) | N/A |
| Operating Expenses | $22,726 | $56,968 | N/A |
| Cash, Cash Equivalents & Marketable Securities | N/A | N/A | $137,512 |
| Accumulated Deficit | N/A | N/A | $(97,706) |
| Convertible Preferred Stock | N/A | N/A | $224,157 |
Note: Revenue is derived solely from research services under an agreement with Vertex Pharmaceuticals. The company has no product sales revenue.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased to $176,000 for the three months ended September 30, 2024, compared to $33,000 in the same period in 2023. For the nine months, revenue rose to $863,000 from $33,000.
- Expense Increase: Total operating expenses increased by approximately 88% year-over-year for the nine-month period ($57.0 million vs. $32.3 million). This was driven by a 79% increase in Research and Development (R&D) expenses and a 65% increase in General and Administrative (G&A) expenses.
- R&D Drivers: The increase in R&D expenses was primarily due to higher external costs (including clinical trial expenses), increased direct costs for preclinical programs, and higher employee-related costs due to headcount growth.
- G&A Drivers: The increase in G&A expenses was attributed to higher consulting, audit, and accounting fees related to IPO preparation, increased legal fees, and higher employee-related costs.
- Interest Income: Interest income increased significantly to $4.7 million for the nine months ended September 30, 2024, compared to $1.5 million in the prior year, due to higher interest rates and increased invested cash balances.
Guidance, Outlook, and Risks
- Subsequent Event (IPO): In October 2024, subsequent to the reporting period, Septerna completed its Initial Public Offering (IPO), issuing 18.4 million shares at $18.00 per share. The company received net proceeds of approximately $302.6 million. Immediately prior to the IPO, all outstanding convertible preferred stock converted to common stock.
- Liquidity Outlook: Management believes that existing cash, cash equivalents, and marketable securities ($137.5 million as of Sept 30, 2024), combined with the IPO proceeds, will be sufficient to fund operations into the second half of 2027.
- Capital Requirements: The company expects to continue incurring significant operating losses for the foreseeable future as it advances product candidates through clinical trials and expands its pipeline.
- Key Risks:
- Development Risk: The company is early in its development efforts; its lead candidate SEP-786 is in early clinical development. There is no guarantee of regulatory approval or commercial success.
- Third-Party Reliance: The company relies on third-party manufacturers and CROs, including entities in China (e.g., WuXi AppTec), which exposes it to supply chain risks and potential regulatory restrictions (e.g., the proposed BIOSECURE Act).
- Intellectual Property: The company's proprietary Native Complex Platform is unproven, and the company faces risks regarding the ability to obtain and enforce patent protection.
Investor Verification Checklist
- Post-IPO Capitalization: Verify the final share count and ownership structure following the October 2024 IPO and the conversion of preferred stock.
- Vertex Agreement Terms: Review the specific terms of the Vertex Research Service Agreement to understand the sustainability of the current revenue stream and any potential milestone payments.
- Cash Burn Rate: Analyze the quarterly cash burn rate to validate the management's assertion that funds will last until the second half of 2027.
- Supply Chain Exposure: Assess the extent of reliance on Chinese CROs/CMOs and the potential impact of the BIOSECURE Act or other geopolitical trade restrictions.
- Clinical Trial Progress: Monitor the status and results of the Phase 1 clinical trial for SEP-786, as this is the primary catalyst for future valuation.